Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to ...

Investors might want to bet on Arcturus Therapeutics (ARCT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

The average one-year price target for Arcturus Therapeutics Holdings (NasdaqGM:ARCT) has been revised to $32.77 / share. This ...

Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Good day, everyone, and welcome to today's Arcturus Therapeutics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the ...

This article first appeared on GuruFocus. Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is set to release its Q3 2025 earnings on Nov 10, 2025. The consensus estimate for Q3 2025 revenue is $21.20 ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...

Shannon Silverman, an Astrophysicist at the Clay Center in Charleston West Virginia, guides us through the cosmos above West Virginia. In this episode she tells us about some of the summer's brightest ...